Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2022-03-14 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
神州细胞关于董事会、监事会延期换届的提示性公告
Board/Management Information Classification · 100% confidence The document is a short announcement (580 characters) from Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding the postponement of the board of directors and supervisory board re-election. It discusses the extension of the current board and management's term to ensure continuity and stability. There is no financial data, no mention of annual or interim reports, no audit information, no voting results, and no other financial or regulatory filings. The content is about board/management information specifically about the delay in board renewal. Therefore, the document fits the category of Board/Management Information (MANG).
2022-03-14 Chinese
神州细胞2022年第一次临时股东大会法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening and proceedings of the 2022 first extraordinary general meeting (临时股东大会) of Beijing Shenzhou Cell Technology Group Co., Ltd. It details the legal compliance of the meeting's convening, attendance, voting procedures, and results. The document includes voting results and legal validation of the meeting process but does not contain financial statements or management discussion of financial results. It is not a full annual or interim report, nor an earnings release or investor presentation. It is also not a proxy solicitation or voting results announcement alone, but a legal opinion on the meeting's legality and procedures. Given the nature of the document as a legal opinion on a shareholders meeting, it fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories. The document length is under 5,000 characters, but it is not merely an announcement of a report publication; it is a substantive legal opinion letter. Therefore, the classification is RNS with high confidence.
2022-02-25 Chinese
神州细胞2022年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement for the "2022 First Extraordinary General Meeting of Shareholders" of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It details the meeting date, attendance, voting results on specific proposals, and legal witness statements. The content focuses on the voting outcomes of shareholder proposals, including approval of extending the validity of a stock issuance plan and authorization to the board. There is no financial data or detailed report content, but rather the official announcement of voting results from a shareholder meeting. This matches the definition of "Declaration of Voting Results & Voting Rights Announcements (DVA)". The document length is short (2111 characters), consistent with an announcement rather than a full report. Therefore, the correct classification is DVA with high confidence.
2022-02-25 Chinese
神州细胞2021年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2021年度业绩快报公告" which translates to "2021 Annual Performance Express Report Announcement." It contains preliminary financial data for the year 2021, including revenue, profit, and other financial metrics. The data is explicitly stated as preliminary and unaudited, with a note that the final audited data will be in the 2021 Annual Report. The document is relatively short (1812 characters) and serves as a quick earnings update rather than a full comprehensive report. It does not contain full financial statements or detailed analysis typical of an Annual Report (10-K) or Interim Report (IR). It is also not a simple announcement of report publication but a brief financial performance update. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. FY 2021
2022-02-24 Chinese
神州细胞2022年第一次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as meeting materials for the "2022 First Extraordinary General Meeting (EGM)" of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It contains detailed information about the meeting agenda, voting procedures, and specific proposals to be voted on, such as extending the validity period of a stock issuance plan and authorization to the board. The content is focused on the meeting itself and the materials provided to shareholders for the EGM, rather than the announcement of voting results or a summary of the meeting outcome. The document length is 4125 characters, which is relatively short but contains substantive meeting materials, not just an announcement. Therefore, it fits the category of AGM Information (AGM-R), which includes presentations and materials shared during general meetings (including extraordinary meetings).
2022-02-16 Chinese
神州细胞关于召开2022年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2022 first extraordinary general meeting of shareholders, detailing the meeting date, voting methods, agenda items, registration procedures, and proxy authorization. It does not contain financial statements or results but is an announcement related to a shareholder meeting. The document length is 3503 characters, which is relatively short and consistent with a meeting notice rather than a full report. There is no indication that this is the actual meeting materials or results, but rather a notification to shareholders about the meeting and voting procedures. Therefore, this fits the category of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2022-02-09 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.